A 48-week open-label study to evaluate the effect of standard dose stavudine (d4T) substitution with low-dose d4T in HIV-infected subjects with identified risk for mitochondrial toxicities who have achieved virologic suppression
Phase of Trial: Phase III
Latest Information Update: 10 Jun 2009
At a glance
- Drugs Stavudine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 10 Jun 2009 Status changed from not stated to unconfirmed.
- 20 Mar 2007 New trial record.